Impact of a Dynamic Dressing in the Management of Unoperated Hallux Valgus (DYNHALLUX) (DYNHALLUX)

Impact of a Dynamic Dressing in the Management of Unoperated Hallux Valgus With Theoretical Indication for Surgery: Randomized Open Trial

Hallux Valgus (HV) is a lateral deviation of the big toe. HV is a deformity of the forefoot centered on the 1st radius (1st metatarsal and big toe). This deformation is characterized by:

• a big toe (hallux) deviated outwards (valgus greater than 12 °)
• a first metatarsal moved medially (varus) (angle M1 / M2> 10 °). We also note the existence of an exostosis formed by the apex of the angle between the 1st metatarsal deviated inwards and the big toe deported outwards. This exostosis corresponds to the head of the 1st metatarsal.

In addition to the pain and the unaesthetic nature induced by this deviation, the modifications of the skeletal axes of the foot cause disorders of its function but also of the joints of the lower limb during standing, walking and running. Axis defects of the lower limbs in varum or valgum also cause deformities in the rearfoot, midfoot and forefoot.

There is no non-surgical curative treatment for this deformity. Different conservative treatment options have been offered for first-line treatment, including different types of physiotherapy, wearing rigid insoles or splints.

Wearing rigid insoles is indicated to "counter" the valgic pressure, thereby reducing pain and high plantar pressure, in patients with HV. Their hardness, expressed in SHORE units, must be greater than 65. By countering the valgic pressure (rearfoot and midfoot), the rigid soles make it possible to contain the development of deformation and stabilize the axis of the first spoke. The speed of hallux deformation is therefore greatly reduced if the soles are worn diligently. But there is little or no impact on the correction of the deformity, but it is stabilized as it is without rapid and major worsening. Indeed, soles with a hardness greater than or equal to 65 SHORE make it possible to avoid the valgum of the hindfoot and midfoot under load and when walking.

Wearing a dynamic splint was studied in a recently published prospective randomized study conducted between 2011 and 2013. This study, concluding that the dynamic splint is not effective in reducing the angle of deformation of the HV, nevertheless shows the reduction in pain during walking and running. The limits of the study lie in the pace of wearing the splint, left to the discretion of patients, during their rest period, and in the duration of the operation, which is not precisely described.

Study Overview

• Status: Terminated
• Conditions: Hallux Abductovalgus
• Intervention / Treatment: Procedure: dynamic dressing

Detailed Description

The hypothesis of the study is that a dynamic joint dressing, associated with a rigid orthopedic insole, would make it possible to "reverse" the deformation and re-focus the angles of deformation of the first ray in patients with a HV and already stabilized, i.e. wearer of made-to-measure soles with SHORE greater than or equal to 65 for at least 2 months.

• Study Type: Interventional
• Enrollment (Actual): 6
• Phase: Not Applicable

Contacts and Locations

Study Locations

• France
  • Metz-Tessy, France, 74374
    • Centre Hospitalier Annecy Genevois

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• hallux valgus on at least one foot theoretically requiring surgical management within 12 months
• reducible hallux valgus
• wearing custom-made orthopedic insoles made by a biomechanical podiatrist - SHORE ≥ 65 - for at least 2 months at the time of inclusion
• beneficiary of a social security scheme
• informed of the study and signed informed consent form

Exclusion Criteria:

• History of hallux valgus correction surgery on the affected foot
• History of traumatic lesion of the M1-P1 metatarsophalangeal joint of the affected foot
• Skin pathology limiting or contraindicating the possibility of dressings according to the judgment of the investigator (eg dyshidrotic eczema, psoriasis or other problematic skin damage located in the foot)
• Acute bursitis
• Clinical and / or radiological stage 1 or more osteoarthritis according to the criteria of Kellgren and Lawrence
• Non-stabilized diabetes and / or diabetes with micro / macrovascular complications
• Patients with neuropathy
• History of gout
• History of rheumatic pathology
• Obliterating arteriopathy of the lower limbs of stage II or more according to the classification of Leriche and Fontaine
• Pregnant woman
• Patients under tutorship or curatorship
• Patients under legal protection
• Patients who do not understand French

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
No Intervention: Control arm; wearing made-to-measure soles with SHORE greater than or equal to 65 (standard of care)
Experimental: Interventional arm; wearing made-to-measure soles with SHORE greater than or equal to 65 + dynamic dressing of the joint	Procedure: dynamic dressing; Dynamic dressing is made by bandages of the foot with gauze pad, stretchable adhesive tape and elastic compression band

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from baseline M1 / P1 angle at day 75 measured by weightbearing foot radiograph	M1 / P1 angle measured before and after intervention	radiograph between day 0 less than 6 months and day 0 and radiograph at day 75

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Variation of the M1 / M2 angle measured by weightbearing foot radiograph	M1 / M2 angle measured before and after intervention	radiograph between day 0 less than 6 months and day 0 and radiograph at day 75
Variation of the M1 / P1 and M1/M2 angle measured by weightbearing foot radiograph at long time	M1/P1 et M1 / M2 angle measured just at the end of the intervention and at long time	radiograph at day 75 and at month 6 and month 12
12-month surgery rate	use of surgery 12 months after randomization	month 12
Quality of life measured by the American Orthopedic Foot and Ankle Society score	American Orthopedic Foot and Ankle Society - hallux metatarsophalangeal interphalangeal scale (min = 0, max = 100, higher scores mean a better outcome).	day 0, day 75, month 6 and month 12
Quality of life measured by the Foot Function Index score	Foot Fonction Index (min = 0, max = 100, higher scores mean a worse outcome).	day 0, day 75, month 6 and month 12
Quality of life measured by the EuroQol Visual Analogue Scale	EuroQol Visual Analogue Scale (min = 0, max = 100, higher scores mean a better outcome.	day 0, day 75, month 6 and month 12
Pain Visual Analogue Scale	Pain Visual Analogue Scale (min = 0, max = 10, higher scores mean a worse outcome).	day 0, day 75, month 6 and month 12
Physician clinical qualitative assessement of skin condition	Presence or absence of irritation, blisters, redness, itching	day 0 and day 75

Collaborators and Investigators

• Sponsor: Centre Hospitalier Annecy Genevois
• Investigators: Principal Investigator: Guy Allamel, PhD, CH Annecy Genevois

Study record dates

Study Major Dates

• Study Start (Actual): April 22, 2021
• Primary Completion (Actual): January 25, 2022
• Study Completion (Actual): January 25, 2022

Study Registration Dates

• First Submitted: January 26, 2021
• First Submitted That Met QC Criteria: January 29, 2021
• First Posted (Actual): February 1, 2021

Study Record Updates

• Last Update Posted (Actual): July 22, 2022
• Last Update Submitted That Met QC Criteria: July 19, 2022
• Last Verified: July 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Musculoskeletal Diseases; Foot Deformities; Hallux Valgus
• Other Study ID Numbers: 18-45

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No